A prospective, multi-centre study of Icatibant for the treatment of acute attacks in patients with hereditary angiodema

Trial Profile

A prospective, multi-centre study of Icatibant for the treatment of acute attacks in patients with hereditary angiodema

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2016

At a glance

  • Drugs Icatibant (Primary)
  • Indications Hereditary angioedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Mar 2016 New trial record
    • 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top